...
首页> 外文期刊>Therapeutic Drug Monitoring >Population pharmacokinetics of carbamazepine in elderly patients
【24h】

Population pharmacokinetics of carbamazepine in elderly patients

机译:卡马西平在老年患者中的群体药代动力学

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Carbamazepine is a commonly used antiepileptic drug in elderly patients. This study analyzed prospective data collected as part of a randomized, double-blinded trial of newly diagnosed epilepsy patients. The aims of this study were to determine the pharmacokinetic parameters and their variability of carbamazepine in elderly patients and to quantify the effect of covariates on these parameters. Methods: Prospectively collected carbamazepine concentrations from 121 patients aged 60 years or older were used to develop a population pharmacokinetic model. Data were analyzed by a nonlinear mixed effects model (NONMEM). A 1-compartment model with first-order absorption and elimination was used to characterize the time course of carbamazepine concentration. Model evaluation and the predictive performance of the final model were assessed using the nonparametric bootstrap approach. Results: The apparent clearance (CL/F) of carbamazepine in this community-dwelling elderly population was estimated to be 3.59 L/h with an interindividual variability of 18.1%. The CL/F increases 23% in patients comedicated with phenytoin. The volume of distribution (V/F) was estimated to be 102 L with an interindividual variability of 74.7%. Conclusions: Carbamazepine clearance was not associated with body weight or any parameterization of body size nor was age or race or any marker of hepatic or renal function in community dwelling elderly patients. Elderly patients on concurrent phenytoin therapy may require a smaller 23% higher dose on average, about half that reported for younger patients.
机译:背景:卡马西平是老年患者中常用的抗癫痫药。这项研究分析了作为新诊断的癫痫患者的随机,双盲试验的一部分而收集的前瞻性数据。本研究的目的是确定卡马西平在老年患者中的药代动力学参数及其变异性,并量化协变量对这些参数的影响。方法:前瞻性收集121名60岁或60岁以上患者的卡马西平浓度,以建立总体药代动力学模型。数据通过非线性混合效应模型(NONMEM)进行分析。使用具有一阶吸收和消除的一室模型来表征卡马西平浓度的时间过程。使用非参数自举法评估模型评估和最终模型的预测性能。结果:在该社区居住的老年人口中,卡马西平的表观清除率(CL / F)估计为3.59 L / h,个体间差异为18.1%。苯妥英钠治疗的患者的CL / F增加23%。分布体积(V / F)估计为102 L,个体间差异为74.7%。结论:卡马西平的清除率与社区居民老年患者的体重或体重的任何参数均无关,年龄,种族,肝功能或肾功能的任何指标均无相关性。接受苯妥英钠同时治疗的老年患者平均需要更高的23%小剂量,约为年轻患者的一半。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号